Corticosteroids to prevent kidney scarring in children with a febrile urinary tract infection: a randomized trial

Abstract

Background: To evaluate the efficacy of adjuvant systemic corticosteroids in reducing kidney scarring. A previous study suggested that use of adjuvant systemic corticosteroids reduces kidney scarring in children radiologically confirmed to have extensive pyelonephritis. Efficacy of corticosteroids for children with febrile urinary tract infection (UTI) has not been studied.

Methods: Children aged 2 months to 6 years with their first febrile UTI were randomized to corticosteroids or placebo for 3 days (both arms received antimicrobial therapy); kidney scarring was assessed using 99mTc-dimercaptosuccinic acid kidney scan 5-24 months after the initial UTI.

Results: We randomized 546 children of which 385 had a UTI and 254 had outcome kidney scans (instead of the 320 planned). Rates of kidney scarring were 9.8% (12/123) and 16.8% (22/131) in the corticosteroid and placebo groups, respectively (p = 0.16), corresponding to an absolute risk reduction of 5.9% (95% confidence interval: - 2.2, 14.1).

Conclusion: While children randomized to adjuvant corticosteroids tended to develop fewer kidney scars than children who were randomized to receive placebo, a statistically significant difference was not achieved. However, the study was limited by not reaching its intended sample size.

Clinical trial registration: Clinicaltrials.gov , NCT01391793, Registered 7/12/2011 Graphical abstract.

Keywords: Children; Clinical trials; DMSA; Dexamethasone; Kidneys; Pyelonephritis; UTI.

Conflict of interest statement

Conflict of Interest: The authors have no conflicts of interest to disclose

Figures

Figure 1.

Enrollment, randomization, and follow-up of children in the study